GI001 therapy for relapsed or refractory B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new cell therapy called GI001 for patients with certain types of B-cell lymphoma or leukemia that have returned or not responded to previous treatments. It aims to see if this therapy can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of B-cell lymphoma or leukemia that is CD19-positive and has come back or not responded to standard treatments.
- You must have measurable disease, such as a tumor that can be seen on scans or at least 5% lymphoma cells in your blood or bone marrow.
- You must be in generally good health (ECOG performance status 0-2) and have adequate organ function (heart, liver, kidneys, blood counts).
- You cannot have central nervous system (brain or spinal cord) involvement, active infections, or other serious medical conditions.
- You must agree to use effective contraception during the trial and for a period after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called GI001 for people with B-cell lymphoma or B-cell leukemia that has come back or hasn't responded to previous treatments. It aims to see if GI001 can help when other options have failed, and it may be an option if you haven't had CAR-T therapy before.
This study tests a new therapy called RS001 for people with B-cell lymphoma or B-cell leukemia that has not gotten better or has returned after treatment. It targets a marker called CD19 on cancer cells, and the goal is to see if it can help control the cancer.
This trial tests an experimental drug called MTM-H-001 given as an injection. It's for people with B-cell lymphoma that has returned or not responded to standard treatments, and it aims to see if the drug can help control the cancer.
This trial tests a new medicine called WGb-0301, given by injection, for people with certain blood cancers (B-cell lymphoma or lymphocytic leukemia) that have come back or not improved with other treatments. The goal is to see if this drug can help control the cancer and what side effects it might cause.
This trial tests a new cell therapy (IBR900) for people with a type of B-cell lymphoma that has come back or not responded to prior treatments. The therapy uses your own immune cells to target and kill the cancer cells.
This study tests an investigational treatment called B019 for people with relapsed or refractory B-cell non-Hodgkin's lymphoma. It aims to see if this treatment can help when other treatments haven't worked.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.